Elicio Therapeutics (ELTX) announced the publication of follow-up data from the Phase 1 AMPLIFY-201 study evaluating ELI-002 in the peer-reviewed ...

At extended median follow-up of 19.7 months, median overall survival (“OS”) increased from 16.33 to 28.94 months Clinical efficacy correlated with the magnitude of T cell responses specific to ...

EXACT Therapeutics AS ( ($DE:56F) ) has shared an update. EXACT Therapeutics announced that data from its ACTIVATE Phase 1 trial, focusing on ...

Led by a team of African researchers, first doses of the novel T cell-inducing GRAdHIVNE1 vaccine candidate have been given.

Phase 1 results demonstrate that SUL-238, a first-in-class, orally administered, mitochondria-directed drug candidate, is ...

The Phase 1 clinical trials program increases patients’ access to novel research by bringing it closer to their homes. Distance should never stand between you and the latest medical breakthroughs. As ...

We report the results of the phase 1 study of cemiplimab for expansion cohorts of patients with locally advanced or metastatic cutaneous squamous-cell carcinoma, as well as the results of the ...

Phase 2 of the voting closes at noon ET on July 2, with starting lineups for each league announced on July 6 at 5 PM ET on ESPN. For now, let's dig into the Phase 1 voting results.

Based on the preliminary Phase 1 safety results, a safety review committee comprising study staff and independent physicians concluded the compound was well tolerated by participants. Martin Low, CEO ...

Previous reviews of phase 1 oncology trials reported a rate of response to treatment of 4 to 6 percent and a toxicity-related death rate of 0.5 percent. These results may not reflect the rates in c ...